FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

@article{Grunwald2013FLT3IF,
  title={FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.},
  author={Michael Richard Grunwald and Mark J Levis},
  journal={International journal of hematology},
  year={2013},
  volume={97 6},
  pages={683-94}
}
Since the Food and Drug Administration approval of imatinib for treatment of chronic myeloid leukemia in 2001, tyrosine kinase inhibitors (TKIs) have become a mainstay in the care of many malignancies. In acute myeloid leukemia (AML), activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene result in survival and proliferation of leukemic blasts and are associated with adverse prognosis. Therefore, the FLT3 receptor is an appealing target for inhibition. Multiple small molecule TKIs… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 105 references

The secondary FLT 3 - ITD F 691 L mutation induces resistance to AC 220 in FLT 3 - ITD ( ? ) AML but retains in vitro sensitivity to PKC 412 and Sunitinib

  • C Albers, H Leischner, M Verbeek, C Yu, AL Illert, C Peschel
  • Leukemia
  • 2013

Variations in FLT3 ligand levels during the course of AML treatment

  • MR Grunwald, MJ Levis
  • J Clin Oncol (ASCO Annual Meeting Abstracts)
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…